---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-24-000042"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:59:27.714848+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024

## Summary
- Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.
- Jakafi FY23 net product revenue $2.59B (+8%); 2024 Jakafi guidance $2.69-$2.75B.
- Opzelura FY23 net product revenue $338M (+162%) driven by atopic dermatitis and vitiligo launch.
- GAAP FY23 net income $598M (diluted EPS $2.65); Non-GAAP net income $795M (diluted EPS $3.52).
- Acquired worldwide rights to tafasitamab (Monjuvi/Minjuvi) from MorphoSys for $25M upfront.

## SEC filing metadata
- accession: 0000879169-24-000042
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/0000879169-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/incy-20240213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-24-000042
- JSON: https://secwatch.observer/filing/0000879169-24-000042.json
- Plain text: https://secwatch.observer/filing/0000879169-24-000042.txt

## Key facts
- Earnings Releases
  INCYTE CORP updated its fourth fiscal quarter and year ended December 31, 2023 guidance (initiated).
  - Period: fourth fiscal quarter and year ended December 31, 2023
  - Guidance: initiated
  - Result: reported results
  source text: On February 13, 2024, Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/0000879169-24-000042-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.